International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: IFN-k is a rheostat for development of psoriasiform inflammation

blog_image_-_commentary_-_pincelli
_pincelli_carlo
Carlo Pincelli, MD, PhD
University of Modena & Reggio Emiliana
Modena, Italy

PUBLICATION

IFN-k is a rheostat for development of psoriasiform inflammation. Gharaee-Kermani M, Estadt SN, Tsoi LC, Wolf-Fortune SJ, Liu J, Xing X, Theros J, Reed TJ, Lowe L, Gruszka D, Ward NL, Gudjonsson JE, Kahlenberg JM. J Invest Dermatol. 2022 Jan;142(1):155-165.e3. doi: 10.1016/j.jid.2021.05.029. Epub 2021 Aug 5. PMID: 34364883; PMCID: PMC8688309.

Why this article was chosen

This innovative research connects insights into immunopathogenesis with genetics and modes of action of treatments. More specifically, evidence is provided for keratinocytes-derived IFN-k as an early event relevant as a treatment target.

Commentary

“Rheostat” is a word coined in the nineteenth century to describe a device that regulates and adjusts the magnitude of electric current. Gharaee-Kermani et al. has recently used this term to define the newly identified role for interferon-k (IFN-k) in psoriatic lesions. They first demonstrated that IFN-regulated genes are increased in lesional and, to a lesser extent, in non-lesional psoriatic skin. They also showed that these genes correlate with psoriasis-associated cytokines, such as IL23 and IL17A. Notably, IFN-k is expressed in the psoriatic epidermis. To shed more light on the role of IFNs in the pathogenesis of psoriasis and to validate their hypothesis of IFN-k acting as a “rheostat” for psoriatic inflammation, Gharaee-Kermani and co-workers stimulated wild-type mice (WT), mice overexpressing IFN-k in the epidermis (Ifnk -TG), and mice lacking IFN-k (Ifnk-KO) with imiquimod (IMQ) to induce psoriasiform inflammation. Whereas Ifnk-KO mice developed only a mild inflammatory phenotype, ear thickness was significantly increased in Ifnk-TG compared to WT mice. The psoriatic phenotype amplified by IFN-k was further confirmed by the histopathologic features of psoriasis and the higher number of dendritic cells (DC), neutrophils, and macrophages in Ifnk-TG mice than in the other groups. Both IFN-regulated genes and genes associated with IL-17 response in psoriatic skin were significantly increased in mice that overexpressed IFN-k at the epidermal level. Finally, T-cells were more numerous in Ifnk-TG than in Ifnk-KO and WT mice. However, it should be noted that mice overexpressing IFN-k at baseline did not display a psoriasiform phenotype, suggesting that the cytokine alone is not sufficient to induce the disease. Because deletion of IFN-k attenuates the IMQ-induced inflammation, the authors concluded that targeting IFN-k may be an early treatment for psoriasis.

As pointed out by Garzorz-Stark and Kilian Eyerich1 in the Commentary related to the present article, in psoriatic skin, there are two immune axes involving IFNs: pDC-derived IFN-a and keratinocytes-derived IFN-k, both leading to type 1 (Th1, IL-12, and IFN-g) and type 3 (IL-23, Th17, IL-17) immune responses. This also implies an active role for keratinocytes in psoriasis.
  1. Garzorz-Stark N, Eyerich K. IFNs: Sentinels shaping distinct immune responses in skin. J Invest Dermatol (2022) 142: 14-15.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis

Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

Also Read

Blog - Commentary - Alexander Egeberg - graphic
long-term treatment

Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares

Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.

Read More
comorbidities

Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.